Context.—Chordomas are uncommon malignant neoplasms with notochordal differentiation
encountered by neuropathologists, bone/soft tissue pathologists, and general surgical …

The last decade has seen the majority of primary bone tumor subtypes become defined by
molecular genetic alteration. Examples include giant cell tumour of bone (H3F3A p. G34W) …

Chordoma is a primary bone cancer with no approved therapy. The identification of
therapeutic targets in this disease has been challenging due to the infrequent occurrence of …

Purpose To explore the antitumor activity of imatinib in patients with advanced platelet-
derived growth factor β (PDGFB)/PDGF receptor β (PDGFRB)–positive chordomas. Patients …

Chondrosarcoma is a heterogeneous collection of malignant bone tumors and is the second
most common primary malignancy of bone after osteosarcoma. Recent work has identified …

Chordoma is a rare tumor that occurs along the axial spine in pediatrics and adults, with an
incidence of approximately 350 cases per year in the United States. While typically …

Background To report on a prospective, investigator-driven, phase II study on lapatinib in
epidermal growth factor receptor (EGFR)-positive advanced chordoma patients. Patients …

PURPOSE: The provirus integration site for Moloney murine leukemia virus 1 (Pim-1) kinase
is overexpressed in various tumors and has been linked to poor prognosis. Its role as proto …

Chordomas are rare malignant tumors that originate from the notochord remnants and occur
in the skull base, spine and sacrum. Due to a very limited understanding of the molecular …

Chordoma is a rare malignant bone tumour with a poor prognosis and limited therapeutic
options. We undertook a focused compound screen (FCS) against 1097 compounds on …